One of the potential pathways of converting an antiatherogenic HDL into its atherogenic forms in CKD involves a disturbance in the PON-1 activity caused by the pro-oxidant activity of myeloperoxidase (MPO) [28]. This evidence concerns the gene MPO and chronic kidney disease.